Panelists discuss how successful transitions between Bruton tyrosine kinase (BTK) inhibitors require careful management of ...

Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...

Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations, disease ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Alan Tan, MD, discusses factors influencing the choice of immunotherapy plus tyrosine kinase inhibitor vs dual IO in patients ...

A Chinese study, led by Arnold ASH Chee, AFCOphthHK, found that a tyrosine kinase inhibitor achieved both durable disease control and visual improvement in patients with epidermal growth factor ...

L-tyrosine, categorized as a non-essential amino acid, is critical in creating neurotransmitters like dopamine, adrenaline, and noradrenaline. These are crucial to controlling mood, managing ...

Clinical experience with alternative antiretroviral strategies, avoiding nucleoside reverse transcriptase inhibitor toxicities and involving new antiretroviral classes, will be reviewed to obtain ...

"With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further establish our leadership in targeting RAS/MAPK pathway-driven cancers ...

It should be noted that Nuvation Bio (NUVB) has submitted an NDA for its dual tropomyosin receptor kinase (TRK)/ROS1 inhibitor taletrectinib in the treatment of line agnostic ROS1+ NSCLC with a ...

In addition, managing on-target, off-tumor toxicities remains a critical ... (2) On activation, the immunoreceptor tyrosine–based activation motifs (ITAMs) on the intracellular CD3ζ chain of the CAR ...